Similar articles

• The things to come of SHAPE: cost and effectiveness of cardiovascular prevention.

  Diamond GA, Kaul S. Diamond GA, et al. Am J Cardiol. 2007 Apr 1;99(7):1013-5. doi: 10.1016/j.amjcard.2006.10.070. Epub 2007 Feb 15. Am J Cardiol. 2007. PMID: 17398203
• [Statins in primary prevention - a must for the general practitioner?].

  Zoller M. Zoller M. Praxis (Bern 1994). 2011 Jul 6;100(14):859-60. doi: 10.1024/1661-8157/a000593. Praxis (Bern 1994). 2011. PMID: 21732299 German. No abstract available.
• The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.

  Kok L, Engelfriet P, Jacobs-van der Bruggen MA, Hoogenveen RT, Boshuizen HC, Verschuren MW. Kok L, et al. Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):371-6. doi: 10.1097/HJR.0b013e328329497a. Eur J Cardiovasc Prev Rehabil. 2009. PMID: 19305351
• Risk assessment for prevention of morbidity and mortality: lessons for pressure ulcer prevention.

  Reynolds TM. Reynolds TM. J Tissue Viability. 2008 Nov;17(4):115-20. doi: 10.1016/j.jtv.2007.09.005. Epub 2008 Feb 20. J Tissue Viability. 2008. PMID: 19061825 Review.
• The economics of cardiovascular disease in the United States.

  Chen J, Rizzo JA. Chen J, et al. Crit Care Clin. 2012 Jan;28(1):77-88, vi. doi: 10.1016/j.ccc.2011.10.007. Crit Care Clin. 2012. PMID: 22123100 Review.